IP.ADJUTOR
Information on this blog is being shared only for the purpose of creating legal awareness in public at large, especially in the field of Intellectual Property Right. As there may be possibility of error, omission or mistake in legal interpretation on the contents of this blog, it should not be treated as substitute for legal advise.
Monday, April 27, 2026
Ganesh Consumer Products Ltd. Vs Assistant Registrar of Trademarks
R. Kishore Kumar Vs. R.R. Cine Productions
Sunday, April 26, 2026
Dinesh Kumar Chowdhury Vs The Registrar of Trade Marks
S.S. White Burs Inc. versus The Registrar of Trade Marks
Sanjeev Gaur Vs The State of Assam
Saturday, April 25, 2026
Crystal Crop Protection Limited Vs. Sudpita Dey, Assistant Controller of Patents and Designs & Ors.
Patents protect new inventions that are useful, novel, and involve an inventive step. In the field of agrochemicals, companies often try to patent combinations of existing active ingredients, claiming they work better together than separately. This case highlights the challenges in obtaining patent protection for such combinations when prior publications already describe similar mixtures. The court examined whether a specific insecticidal formulation using Fipronil and Emamectin Benzoate in a suspension concentrate (SC) form deserved a patent, or whether it was anticipated by existing knowledge in the public domain.
The judgment provides a clear example of how Indian courts apply the tests of novelty (newness) and inventive step (non-obviousness) under the Patents Act, 1970. It is particularly useful for understanding how prior art documents from other countries (here, Chinese patents) can block a patent grant in India if they disclose the same or very similar invention.
Factual Background
Crystal Crop Protection Limited filed Patent Application No. 1607/DEL/2010 on July 8, 2010, titled “Insecticidal Composition.” The invention claimed a broad-spectrum insecticide made by combining two active ingredients: Fipronil (a phenyl-pyrazole insecticide that disrupts the insect nervous system) at exactly 3.5% w/w and Emamectin Benzoate (an avermectin-class insecticide) at exactly 1.5% w/w, formulated as a suspension concentrate (SC).
The company argued that this specific combination and formulation offered a synergistic effect — meaning the two chemicals together killed insects more effectively than the sum of their individual effects. It claimed the product controlled both biting/chewing insects (like Spodoptera, fruit borers, Helicoverpa) and sucking insects (mites, leaf miners, thrips) in a single, cost-effective, and environment-friendly product. The appellant emphasized that no single prior product effectively handled such a wide range of pests without higher costs or environmental harm.
The complete specification highlighted lower dosage requirements, reduced residues, rain-fastness (not washing off easily), and better safety for non-target organisms. The independent Claim 1 specifically defined the composition with the exact percentages and SC form, while dependent claims covered adjuvants and their concentrations.
Procedural Background
After filing, the application underwent examination. The First Examination Report (FER) was issued in 2017, and the applicant responded and amended claims in 2019. Between 2017 and 2021, four pre-grant oppositions were filed by different parties, including Respondent No. 3 (represented by Advocate Ajay Amitabh Suman). The applicant replied to these oppositions.
A hearing was held before the Assistant Controller of Patents and Designs on November 23, 2021. On January 11, 2022, the Assistant Controller refused the application on three main grounds:
- Lack of novelty (the invention was not new);
- Lack of inventive step (it was obvious to a skilled person);
- Non-patentability under Section 3(d) of the Patents Act (mere new form of a known substance without enhanced efficacy).
The appellant filed an appeal under Section 117A of the Patents Act before the Delhi High Court, arguing that the Controller’s order lacked proper reasoning, failed to consider the synergistic effect, and misapplied the law on novelty and obviousness. The appellant relied on the Delhi High Court’s earlier decision in Biomoneta Research Pvt. Ltd. vs. Controller General of Patents (2023 SCC OnLine Del 1482) to support patentability of synergistic combinations.
Respondent No. 3 strongly defended the refusal, pointing out that multiple Chinese prior art documents already disclosed the same combination of Fipronil and Emamectin Benzoate in similar concentrations and formulations.
Reasoning
The court, through Justice Tushar Rao Gedela, carefully analyzed the invention and the cited prior arts. It first summarized the problem the invention sought to solve and the claimed solution, including the alleged synergy.
Lack of Novelty
The court found that the invention lacked novelty primarily because of two Chinese documents:
- CN1969627 (CN'627): Embodiment 5 explicitly disclosed a composition with exactly 3.5% Fipronil and 1.5% Emamectin Benzoate. Claim 8 described formulations as “suspending agent” (which corresponds to suspension concentrate/SC). The abstract and claims covered the same range of pests. The court noted that the specific percentages fell within the broad ranges disclosed, and the SC form was expressly taught.
- CN101019546 (CN'546): Example 5 again disclosed the identical 3.5% Fipronil + 1.5% Emamectin Benzoate combination, with co-toxicity coefficient showing synergy, and mentioned possible formulations including aqueous emulsions.
The court held that a single prior art document anticipating all essential features of the claim destroys novelty. Here, the exact active ingredients, their precise concentrations in one case, and the formulation type were already public knowledge. Minor differences in other components (like presence of synergists in some examples) did not save the claim, as the core combination was disclosed.
Lack of Inventive Step (Obviousness)
Even if not entirely anticipated, the court found the invention obvious to a person skilled in the art (PSA). It examined several additional documents:
- CN101066055A (CN'055) and CN101151970A (CN'970): These taught combinations of Fipronil and Emamectin Benzoate (or its derivatives) in overlapping ratios, with adjuvants, and various formulations including suspensions. They encouraged mixtures to reduce resistance and improve efficacy.
- CN1911037 (CN'037): Disclosed SC formulations of the same pair with ratios covering the claimed amounts, field trials showing good control, and synergy data.
- CN1579160 (CN'160): Explicitly taught synergistic pesticidal compositions of Fipronil and Emamectin Benzoate in suspension form, with examples and preparation methods.
The court explained that combining teachings from these documents (all in the same technical field of crop protection) would obviously lead a skilled formulator to the claimed specific percentages and SC form. SC formulations were a standard, well-known type in the industry for water-based, environment-friendly delivery. The alleged synergy was also demonstrated or suggested in prior arts.
The court rejected the argument of “teaching away” or improper mosaicing, noting that when documents disclose similar products in the same field, it reflects the state of the art rather than impermissible combining of unrelated teachings (Sterlite Technologies Ltd. v. HFCL Ltd., 2022 SCC OnLine Del 2895).
It also clarified the correct approach to inventive step, drawing from Agriboard International LLC vs. Deputy Controller of Patents (2022 SCC OnLine Del 940): the Controller must compare (i) the prior art, (ii) the claimed invention, and (iii) how a PSA would obviously bridge them. The impugned order satisfied this test.
Other Grounds
The court found it unnecessary to examine Section 3(d) (new form without enhanced efficacy) or sufficiency of disclosure once novelty and inventive step objections were upheld.
On the appellant’s procedural challenge (alleged non-application of mind or copy-pasting), the court held that mere similarity in reasoning with opposition submissions does not invalidate the order if independent analysis is evident. Here, the Controller had examined each prior art in detail.
Judgements with Complete Citation and Their Context Discussed
The court referred to and applied several key precedents to guide its analysis:
- Biomoneta Research Pvt. Ltd. vs. Controller General of Patents, Designs and Anr. (2023 SCC OnLine Del 1482): Cited by the appellant to argue that synergistic combinations of known ingredients can be patentable if they show unexpected enhancement. The court distinguished it on facts, as the prior arts here already suggested or demonstrated synergy for the same pair.
- Sterlite Technologies Ltd. v. HFCL Ltd. (2022 SCC OnLine Del 2895): Used to explain that using multiple documents disclosing similar products in the same field does not amount to impermissible “mosaicing.” It reflects the cumulative state of the art.
- Agriboard International LLC vs. Deputy Controller of Patents and Designs (2022 SCC OnLine Del 940): Provided the three-step framework for assessing inventive step — prior art disclosure, claimed invention, and obviousness to PSA. The court confirmed the Controller followed this structured approach.
These citations were discussed in the context of ensuring that patent refusals are reasoned, that obvious combinations in a crowded field like pesticides do not qualify for protection, and that synergy claims must be evaluated against existing disclosures.
Final Decision of the Court
The Delhi High Court upheld the Assistant Controller’s refusal order in its entirety. The appeal was dismissed without any order as to costs. The court concluded that the claimed composition lacked both novelty and inventive step, making it unpatentable under the Patents Act. It did not find any infirmity in the Controller’s reasoning warranting interference or remand for fresh consideration.
Point of Law Settled in the Case
A specific selection of known active ingredients in precise percentages and a standard formulation type (like SC) does not automatically qualify for a patent if prior publications already disclose the same combination, similar ratios, and the formulation option. Synergy, while potentially patentable in principle, must be genuinely unexpected and not suggested or shown in existing literature.
Controllers and courts must apply a structured analysis for inventive step, but when the field is well-developed and multiple documents point in the same direction, the invention is likely obvious. Mere procedural arguments about “copy-pasting” will not succeed if the final decision shows application of mind to the key issues.
The case underscores that patents are not granted for incremental or routine improvements in agrochemical formulations when the core idea is already in the public domain through foreign prior art.
Disclaimer: Readers are advised not to treat this as substitute for legal advise as it may contain errors in perception, interpretation, and presentation.
Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi
Suggested Titles for the Article:
- Delhi High Court Remands Insecticide Patent: Reasoned Order Required for Synergistic Fipronil-Emamectin Composition
- Synergistic Insecticidal Formulation Gets Second Chance: Key Takeaways from Crystal Crop Protection Patent Appeal
- Why the Delhi High Court Set Aside Refusal of Broad-Spectrum Pesticide Patent
- Patent Office Must Apply Mind Independently: Lessons from Crystal Crop’s Successful Appeal
Kamal Raheja Vs. Hahnemann Pure Drug Co.
Infringement Protection Independent of Commercial Use
Introduction
In a straightforward yet important ruling on trademark protection in the pharmaceutical and skincare sector, a Division Bench of the Delhi High Court on 8 July 2025 dismissed an appeal by Kamal Raheja challenging an interim injunction restraining him from using the mark “MARKS GO” for skincare cream. The court held that the registered proprietor of a trademark enjoys exclusive rights to prevent infringement regardless of whether the mark is currently in commercial use due to a suspended drug manufacturing licence.
The Court clarified that lack of commercial exploitation does not automatically defeat an infringement action at the interim stage. The remedy for non-use lies in a separate rectification application under Section 47 of the Trade Marks Act, not as a defence in an infringement suit. This decision reinforces that valid registration provides strong prima facie protection, and infringing parties cannot escape liability by pointing to regulatory issues faced by the brand owner.
Factual Background
Hahnemann Pure Drug Co., the respondent, is the registered proprietor of the trademark “MARKS GO” in Class 5 under the Trade Marks Act, 1999, with registration dating back to 14 September 2010. The mark covers skincare cream and related products. The company discovered that Kamal Raheja, the appellant, was manufacturing and selling similar skincare products under the identical mark “MARKS GO”.
Hahnemann filed a commercial suit (CS(COMM) 346/2023) before the District Judge (Commercial Court-02), Rohini, seeking a permanent injunction against the appellant for trademark infringement. Along with the suit, it moved an application under Order XXXIX Rules 1 and 2 of the CPC for an interim injunction. On 8 June 2023, the trial court granted an ex parte ad interim injunction restraining the appellant and others from using “MARKS GO” or any deceptively similar mark for skincare products.
The appellant filed an application under Order XXXIX Rule 4 CPC seeking vacation of the injunction. Meanwhile, the respondent faced regulatory action: its drug manufacturing licence was suspended following a show cause notice under the Drugs and Cosmetics Act, 1940. The appellant argued that due to this suspension, the respondent could not commercially exploit the mark and thus had no justification to seek an injunction.
On 7 March 2025, the learned Commercial Court allowed the respondent’s injunction application, making the ex parte order absolute, and dismissed the appellant’s vacation application. It found the rival marks identical, used for similar goods, and rejected the appellant’s plea of acquiescence while noting the respondent’s registration and the appellant’s lack of priority.
Procedural Background
The suit was instituted in 2023. The trial court promptly granted an ex parte ad interim injunction on 8 June 2023. After hearing both sides on the interim applications, the Commercial Court passed the detailed impugned order on 7 March 2025, confirming the injunction and rejecting the vacation plea.
Aggrieved, Kamal Raheja filed the present appeal under Section 13 of the Commercial Courts Act read with Order XLIII Rule 1(r) CPC before the Delhi High Court (FAO(COMM) 105/2025), along with applications for stay and other reliefs. The appeal was heard as an oral judgment on 8 July 2025.
Reasoning
The Division Bench noted that the appellant did not contest the core issues of registration, identity of marks, or similarity of goods. The sole argument was that the respondent’s drug licence suspension prevented commercial use of “MARKS GO”, rendering the injunction unjustified.
The court rejected this submission outright. It explained that rights against infringement flow directly from valid registration under Section 28(1) of the Trade Marks Act. Once a mark is registered and the registration is subsisting, the proprietor gains the exclusive right to use it and to obtain relief against infringement. Commercial user is not a prerequisite for maintaining an infringement action.
Section 29 of the Act defines infringement with reference to a “registered trade mark.” The provisions protecting against infringement do not condition relief on actual market use by the registrant. While non-use for five continuous years can be a ground for rectification and removal of the mark under Section 47 (upon application by an aggrieved person), such removal is not automatic and does not retroactively validate infringement.
At the interim injunction stage, the plaintiff needs only to show a prima facie case. Section 31(1) provides that registration itself is prima facie evidence of validity. The appellant could not, at this stage, successfully argue invalidity or disentitlement based on the respondent’s regulatory issues under the Drugs and Cosmetics Act. Those issues might give the respondent remedies elsewhere, but they do not strip the registered mark of its statutory protection.
Key Judgments Discussed with Citations and Context
The Division Bench primarily relied on the statutory framework of the Trade Marks Act rather than citing specific external precedents in detail. It explained Sections 28(1), 29, 31(1), 47, and 135(1) in clear, accessible language:
- Section 28(1): Registration of a valid trademark gives the proprietor exclusive rights to use the mark for the registered goods/services and to seek relief against infringement. The court stressed that this right arises from registration itself, not from actual commercial exploitation.
- Section 29: Infringement is defined with respect to a registered trademark. Each sub-section begins with “a registered trade mark,” making registration the key trigger rather than user.
- Section 47(1): Non-use for five years (subject to conditions) can lead to removal of the mark from the register, but only upon an application by an aggrieved person. The Registrar cannot act suo motu, and removal is not automatic. The court clarified that an infringer cannot use non-use as a shield in an infringement suit; the proper remedy is a separate rectification proceeding.
- Section 31(1): Registration is prima facie evidence of validity in legal proceedings, strengthening the plaintiff’s case at the interim stage.
- Section 135(1): Relief in infringement suits includes injunction, damages, or account of profits, reinforcing the strong protection for registered marks.
The judgment also referenced the broader definition of “use of a mark” under Section 2(2)(b) and (c), noting that it encompasses visual representation and association with goods, not merely actual sales. Provisions like Sections 30, 33, 34, and 35 that can insulate defendants in specific situations were noted, but none applied here.
The reasoning was kept simple: registration creates strong rights that infringement actions protect, while non-use challenges must follow the specific statutory route under Section 47 rather than serving as a defence.
Final Decision of the Court
The Division Bench dismissed the appeal (FAO(COMM) 105/2025) and the connected applications. It found no reason to interfere with the impugned order dated 7 March 2025 of the Commercial Court, which had made the interim injunction absolute. The interim restraint against the appellant using “MARKS GO” or any deceptively similar mark for skincare products remained in force.
Point of Law Settled in the Case
A valid and subsisting registration of a trademark gives the owner the exclusive right to stop others from using an identical or deceptively similar mark for similar goods, even if the owner is temporarily unable to sell the product due to regulatory issues like a suspended drug licence. Lack of current commercial use does not weaken the right to an injunction against infringement at the interim stage.
If someone wants to challenge a registered mark on grounds of non-use, they must file a separate application for rectification and removal under Section 47 of the Trade Marks Act after the required five-year period. They cannot use non-use as a defence in the main infringement suit to escape an injunction.
At the interim stage, registration itself provides strong prima facie evidence of validity, and courts will protect registered marks unless specific statutory exceptions apply. This protects brand owners from copycats while directing non-use disputes to the proper rectification process.
The ruling also reminds parties that arguments in appeals should focus on the core issues; raising only peripheral points (like licence suspension) without contesting infringement findings is unlikely to succeed.
Disclaimer: Readers are advised not to treat this as substitute for legal advise as it may contain errors in perception, interpretation, and presentation.
Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi
Suggested Titles for the Article:
- Delhi High Court: Suspended Drug Licence No Bar to Trademark Injunction for “MARKS GO”
- Registration Trumps Non-Use: High Court Upholds Injunction in Skincare Trademark Dispute
- Infringement Protection Independent of Commercial Use: Key Ruling in Kamal Raheja Case
- Section 28 Rights Prevail: Division Bench Dismisses Appeal Against “MARKS GO” Injunction
Suitable Tags:
Trademark Infringement, Interim Injunction, Section 28 Trade Marks Act, Non-Use Defence, Section 47 Rectification, Drugs and Cosmetics Act, Commercial Court, Delhi High Court, MARKS GO Trademark, Order XXXIX CPC
Headnote of the Article
In FAO(COMM) 105/2025, the Delhi High Court Division Bench dismissed the appeal and upheld the interim injunction restraining the appellant from using the mark “MARKS GO” for skincare products. The court held that rights against infringement under Section 28(1) of the Trade Marks Act arise from valid registration and are not dependent on current commercial use by the registrant. Non-use may support a rectification application under Section 47 but does not defeat an infringement action or interim relief at the interlocutory stage. The judgment clarifies that regulatory suspension of a drug licence does not divest the registered proprietor of statutory trademark protection.
Blog Archive
- April 2026 (61)
- March 2026 (38)
- February 2026 (44)
- January 2026 (80)
- December 2025 (108)
- November 2025 (62)
- October 2025 (44)
- September 2025 (75)
- August 2025 (103)
- July 2025 (95)
- June 2025 (93)
- May 2025 (118)
- April 2025 (91)
- March 2025 (148)
- February 2025 (116)
- January 2025 (58)
- October 2024 (8)
- September 2024 (34)
- August 2024 (68)
- July 2024 (39)
- June 2024 (57)
- May 2024 (49)
- April 2024 (6)
- March 2024 (44)
- February 2024 (39)
- January 2024 (21)
- December 2023 (29)
- November 2023 (23)
- October 2023 (27)
- September 2023 (33)
- August 2023 (29)
- July 2023 (29)
- June 2023 (2)
- May 2023 (1)
- April 2023 (5)
- March 2023 (6)
- February 2023 (1)
- November 2022 (17)
- October 2022 (11)
- September 2022 (30)
- August 2022 (46)
- July 2022 (36)
- June 2022 (26)
- October 2020 (1)
- September 2020 (1)
- April 2020 (1)
- March 2020 (1)
- February 2020 (2)
- December 2019 (1)
- September 2019 (3)
- August 2019 (2)
- July 2019 (1)
- June 2019 (2)
- April 2019 (3)
- March 2019 (2)
- February 2019 (2)
- January 2019 (2)
- December 2018 (3)
- November 2018 (1)
- October 2018 (2)
- September 2018 (2)
- August 2018 (8)
- July 2018 (2)
- June 2018 (1)
- May 2018 (41)
- April 2018 (7)
- March 2018 (3)
- February 2018 (4)
- January 2018 (2)
- December 2017 (6)
- November 2017 (4)
- September 2017 (5)
- August 2017 (6)
- July 2017 (1)
- June 2017 (1)
- May 2017 (10)
- April 2017 (16)
- November 2016 (3)
- October 2016 (24)
- March 2015 (2)
- January 2014 (1)
- December 2013 (4)
- October 2013 (2)
- September 2013 (7)
- August 2013 (27)
- May 2013 (7)
- September 2012 (31)
- December 2009 (3)
- September 2009 (1)
- March 2009 (3)
- January 2009 (2)
- December 2008 (1)
Featured Post
WHETHER THE REGISTRAR OF TRADEMARK IS REQUIRED TO BE SUMMONED IN A CIVIL SUIT TRIAL PROCEEDING
WHETHER THE REGISTRAR OF TRADEMARK IS REQUIRED TO BE SUMMONED IN A CIVIL SUIT TRIAL PROCEEDING IN ORDER TO PROVE THE TRADEMARK REGISTRA...
-
Introduction In the dynamic realm of pharmaceutical innovation, where intellectual property rights safeguard groundbreaking discoveries, th...
-
A Party is not allowed to argue a case, what is not pleaded. Introduction: This case revolves around a fundamental principle of civil proce...
My Blog List
-
मृत्यु के करीब मृत्यु से दूर - ये कहानी अनिता मूरजानी के जीवन के एक असाधारण और रूपांतरणकारी सफर को दर्शाती है। लेखिका बताती हैं कि कैसे सांस्कृतिक दबावों, अपेक्षाओं और गहरे डर में जीने...5 days ago
-
IPL:Spice In, Nationality Out - I was sitting in my office. It was a hot afternoon. The fan was running slowly and making strange sounds like an old typewriter. Files were lying on my d...11 months ago
-
-
My other Blogging Links
- Ajay Amitabh Suman's Poem and Stories
- Facebook-My Judgments
- Katha Kavita
- Lawyers Club India Articles
- My Indian Kanoon Judgments
- Linkedin Articles
- Speaking Tree
- You Tube-Legal Discussion
- बेनाम कोहड़ा बाजारी -Facebook
- बेनाम कोहड़ा बाजारी -वर्ड प्रेस
- बेनाम कोहड़ा बाजारी-दैनिक जागरण
- बेनाम कोहड़ा बाजारी-नवभारत टाइम्स
- बेनाम कोहड़ा बाजारी-ब्लॉग स्पॉट
- बेनाम कोहड़ा बाजारी-स्पीकिंग ट्री